Author(s): Prithviraj. B. Chavan, Mahesh. H. Kolhe, Kavita. V. Dhamak, Rohit. J. Bhor

Email(s): pruthvirajchavan69150@gmail.com

DOI: 10.52711/2231-5675.2023.00020   

Address: Prithviraj. B. Chavan*, Mahesh. H. Kolhe, Kavita. V. Dhamak, Rohit. J. Bhor
1Department of Quality Assurance Technique, Pravara Rural College of Pharmacy, Pravaranagar, Ahmednagar - (MH) India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 2,     Year - 2023


ABSTRACT:
Carvedilol and ivabradine is a drug combination used to treat cardiovascular diseases like hypertension, chronic stable angina pectoris and, chronic heart failure. Both are different in their mode of action. Carvedilol prevents exercise-induced tachycardia via inhibition of beta-adrenoreceptor carvedilol also acting on alpha-1 adrenergic receptors and an overall reduction in blood pressure. In case of a higher dose also shows antioxidant and calcium channel blocking activity. Ivabradine is a heart rate reducing drug that works by blocking cardiac pacemaker currents (If) selectively and specifically. The major goal of this review paper is to emphasize the characteristics of carvedilol and ivabradine, such as their pharmacological profiles, mechanisms of action, pharmacokinetic and pharmacodynamic studies, and previously described analytical methodologies for carvedilol and ivabradine determination. Various methods such as UV spectroscopy HPLC, RP-HPLC, UPLC. This review deals with the various analytical method reported and adopted for the estimation of carvedilol and ivabradine.


Cite this article:
Prithviraj. B. Chavan, Mahesh. H. Kolhe, Kavita. V. Dhamak, Rohit. J. Bhor. Analytical Technique for Carvedilol and Ivabradine determination from pure and Pharmaceutical Dosage Forms: A Review. Asian Journal of Pharmaceutical Analysis. 2023; 13(2):115-1. doi: 10.52711/2231-5675.2023.00020

Cite(Electronic):
Prithviraj. B. Chavan, Mahesh. H. Kolhe, Kavita. V. Dhamak, Rohit. J. Bhor. Analytical Technique for Carvedilol and Ivabradine determination from pure and Pharmaceutical Dosage Forms: A Review. Asian Journal of Pharmaceutical Analysis. 2023; 13(2):115-1. doi: 10.52711/2231-5675.2023.00020   Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-2-9


REFERENCES:
1.    Moses Kandula, Karthika. P, Robin Abraham. Nurses Action towards Cardio Vascular Emergencies. Asian J. Nursing Education and Research. 2019; 9(1):121-126. DOI: 10.5958/2349-2996.2019.00024.7
2.    Bagriy AE., et al., Addition of Ivabradine to β-Blocker Improves Exercise Capacity in Systolic Heart Failure Patients in a Prospective, Open-Label Study, Advances in Therapy, 2015; 32(2):108–119. https://doi.org/10.1007/s12325-015-0185-5
3.    Gehr TWB, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH., The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency, European Journalof Clinical Pharmacology, 1999; 55(4):269–277. https://doi.org/10.1007/s002280050628
4.    Mctavish D, Campoli-richards D, Sorkin EM., Carvedilol Therapeutic Efficacy, Drugs, 1993; 45(2):232–258. https://doi.org/10.2165/00003495-199345020-00006
5.    Petite SE, Bishop BM, Mauro VF., Role of the funny current inhibitor ivabradine in cardiac pharmacotherapy: A systematic review, American Journal of Therapeutics, 2018; 25(2):247–266.https://doi.org/10.1097/mjt.0000000000000388
6.    Oliphant CS, Owens RE, Bolorunduro OB, Jha SK., Ivabradine: A Review of Labeled and Off-Label Uses, American Journal of Cardiovascular Drugs, 2016; 16(5):337–347. https://doi.org/10.1007/s40256-016-0178-z
7.    Di Franco A., et al., Beta-blockers and ivabradine in chronic heart failure: From clinical trials to clinical practice, American Journal of Cardiovascular Drugs, 2014; 14(2):101–110. https://doi.org/10.1007/s40256-013-0057-9
8.    Alshammari TM., Ivabradine: Do the Benefits Outweigh the Risks? Journal of Cardiovascular Pharmacology and Therapeutics, 2017; 22(3):210–218. https://doi.org/10.1177/1074248416672008
9.    Bocchi EA, Salemi VMC., Ivabradine for treatment of heart failure, Expert Opinion on Drug Safety, 2019; 18(5):393–402. https://doi.org/10.1080/14740338.2019.1612873
10.    GarachBhavikkumar D. The rationale of use of combination therapy in hypertensive patients. Research J. Pharmacology and Pharmacodynamics. 2013; 5(1): 19-26.
11.    Beattie K, Phadke G, Novakovic J., Carvedilol: Profiles of Drug Substances, Excipients and Related Methodology, Elsevier Inc., 2013; 38:113–157.
12.    Audumbar Mali, Vikas Kekan, Rohan Dongare, Sachin Gholve, Ritesh Bathe. Simultaneous UV Spectrophotometric Methods for Estimation of Carvedilol and Hydrochlorothiazide in Bulk and Tablet Dosage Form. Asian J. Pharm. Tech. 2016; Vol. 6(1): 15-20. DOI: 10.5958/2231-5713.2016.00002.7
13.    Chen-Scarabelli C. et al., A critical review of the use of carvedilol in ischemic heart disease, American Journal of Cardiovascular Drugs, 2012; 12(6):391–401. https://doi.org/10.1007/bf03262473
14.    Tina Raju. Development and Evaluation of press coated tablets of Carvedilol using solid dispersion prepared by spray drying technique. Asian J. Pharm. Tech. 2018; 8 (3):123-131.DOI: 10.5958/2231-5713.2018.00020.X
15.    Leonetti G, Egan CG., Use of carvedilol in hypertension: An update, Vascular Health Risk Management, 2012; 8(1):307–322.https://doi.org/10.2147/vhrm.s31578
16.    Dattatraya M. Shinkar, Sudarshan B. Aher, Ravindra B. Saudagar. Design and Development of Liquisolid Compact of Carvedilol. Res. J. Pharm. Dosage Form. and Tech. 7(4): Oct.-Dec., 2015; Page 243-255.DOI: 10.5958/0975-4377.2015.00035.X
17.    Christopher JD, Andrew PL, Antona JW, Carvedilol: A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders, Drugs, 1998; 5(2):79–87. https://doi.org/10.2165/00003495-199754010-00015
18.    Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR., The Clinical Use of Ivabradine, Journal of American College of Cardiology, 2017; 70(14):1777–1784. http://dx.doi.org/10.1016/j.jacc.2017.08.038
19.    Perry CM., Ivabradine: In adults with chronic heart failure with reduced left ventricular ejection fraction, American Journal of Cardiovascular Drugs, 2012; 12(6):415–426. https://doi.org/10.2165/11209990-000000000-00000
20.    Chinmaya Keshari Sahoo, Muvvala Sudhakar, D. Venkata Ramana, K. Satyanarayana, KanhuCharan Panda. Validation of Analytical Procedures- A Review. Asian J. Pharm. Ana. 2018; 8(2): 109-116 DOI: 10.5958/2231-5675.2018.00021.2
21.    Hamid Khan. Analytical Method Development in Pharmaceutical Research: Steps involved in HPLC Method Development. Asian J. Pharm. Res. 2017; 7(3): 203-207.DOI: 10.5958/2231-5691.2017.00031.4
22.    Rajesh Z. Mujoriya. Analytical Method Development and Validation of Pharmaceutical Technology: An Overview. Research J. Pharma. Dosage Forms and Tech. 2013; 5(4): 213-220
23.    Hamid Khan, Javed Ali. UHPLC: Applications in Pharmaceutical Analysis. Asian J. Pharm. Ana. 2017; 7(2): 124-131 DOI: 10.5958/2231-5675.2017.00020.5
24.    Nadella NP, Ratnakaram VN, Srinivasu N., Development and validation of UPLC method for simultaneous quantification of carvedilol and ivabradine in the presence of degradation products using DoE concept, Journal of Liquid Chromatography and Related Technologies, 2018; 41(3):143–153. https://doi.org/10.1080/10826076.2018.1427595
25.    Rehman MM, Nagamallika G., Validated RP-HPLC Method for the Determination of Ivabradine Hydrochloride in Pharmaceutical Formulation, International Journal of Pharmaceutical Sciencesand Drug Research, 2017; 9(5).https://doi.org/10.25004/IJPSDR.2017.090505
26.    Swetha E, Vijitha C, Veeresham C., HPLC Method Development and Validation of S (-)-Carvedilol from API and Formulations, American Journal of Analytical Chemistry, 2015; 6(5):437–445. http://dx.doi.org/10.4236/ajac.2015.65043
27.    Stojanovic J, Vladimirov S, Marinkovic V, Velickovic D, Sibinovic P., Monitoring of the photochemical stability of carvedilol and its degradation products by the RP-HPLC method, Journal of Serbian Chemical Society, 2017; 72(1):37–44. 10.2298/JSC0701037S
28.    Ahmed S, Khan A, Sheraz MA, Bano R, Ahmad I., Development and Validation of a Stability-Indicating HPLC Method for the Assay of Carvedilol in Pure and Tablet Dosage Forms, Current Pharmaceutical Analysis, 2018; 14(2):139–152.
29.    Tomic J., et al. Chemometrically Assisted RP-HPLC Method Development for Efficient Separation of Ivabradine and its Eleven Impurities, Acta Chromatogrphica, 2020; 32(1):53–63. https://doi.org/10.1556/1326.2019.00659
30.    Kanthale SB, Thonte SS, Mahapatra DK., Stability indicating RP-HPLC method for the simultaneous estimation of ivabradine and metoprolol in bulk and tablet formulation, Journal ofAppied Pharmaceutical Sciences, 2019; 9(4):137–144. https://dx.doi.org/10.7324/JAPS.2019.90418.
31.    Pasupuleti S, Vijaya KG. Mounika Nayan, Method development and its validation for the quantitative estimation of Ivabradine by RP-HPLC in bulk drug and marketed formulation with the stability studies, International Journal of Research, 2019; 8(3):3072-3092.
32.    Prajakta Gopinath Thete, RavindranathBhanudasSaudagar. Analytical Method Development and Validation for the Determination of Ivabradine HCl by RP-HPLC in bulk and Pharmaceutical Dosage form. Asian J. Pharm. Tech. 2019; 9(2):89-92. DOI: 10.5958/2231-5713.2019.00015.1
33.    Mahaveer Singh, S.G. Kashkhedikar, Love Soni, Abhinav Garg Tripti Gandhi, Amrish Patel. Development of RP-HPLC Method for Estimation of Carvedilol in Tablet Formulations. Research J. Pharm. and Tech. 1(1): Jan.-Mar. 2008; Page 18-21.
34.    Kakad SB, Kolhe MH, Dukre TP., A Review on Pharmaceutical Validation. International Journal of Pharmaceutical Quality Assurance, 2020; 11(3):338-342.http://dx.doi.org/10.25258/ijpqa.11.3.6

Recomonded Articles:

Author(s): Asha M. Jagtap, Sudhir R. Kaulage, Shivam S. Kanse, Vishal D. Shelke, Akshata S. Gavade, Ganesh B. Vambhurkar, Rohit R. Todkar, Vidya N. Dange

DOI: 10.5958/2231-5675.2018.00035.2         Access: Open Access Read More

Author(s): Sushil D. Patil, Sunil V. Amurutkar, C.D. Upasani

DOI: 10.5958/2231-5675.2016.00030.2         Access: Open Access Read More

Author(s): Pankaj Bhamare, Rupal Dubey, Neeraj Upmanyu, Pothuvan Umadoss

DOI: 10.5958/2231-5675.2021.00001.6         Access: Open Access Read More

Author(s): Hamid Khan, Javed Ali

DOI: 10.5958/2231-5675.2017.00020.5         Access: Open Access Read More

Author(s): K. Pramod, Shahid H. Ansari, Javed Ali

DOI:         Access: Open Access Read More

Author(s): Shobha Rani G, Lohita M, Jaya Preethi P, Madhavi R, Sunisitha B, Mounika D

DOI:         Access: Open Access Read More

Author(s): Pinaz A. Kasad, K.S. Muralikrishna

DOI:         Access: Open Access Read More

Author(s): Kirthi A, Shanmugam R, Mohana Lakshmi S , Ashok Kumar CK, Padmini K, Shanti Prathyusha M, Shilpa V

DOI:         Access: Open Access Read More

Author(s): Suraj J. Patil, Shivani D. Patil, Pratibha B. Patil, Pranali S. Patil, Ganesh B. Vambhurkar, Indryani D. Raut

DOI: 10.5958/2231-5675.2018.00040.6         Access: Open Access Read More

Author(s): Khushboo Patel*, Dhara Patel, Jaya Dwivedi, Priyanka Newal, Dhananjay Meshram

DOI: 10.5958/2231-5675.2017.00039.4         Access: Open Access Read More

Author(s): P. Janaki Pathi, N. Appala Raju, G.Parvathalu

DOI:         Access: Open Access Read More

Asian Journal of Pharmaceutical Analysis (AJPA) is an international, peer-reviewed journal, devoted to pharmaceutical analysis...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231–5675 


Recent Articles




Tags